Riskpilot← Back to searchSign inGet full accessLANGEPHARM ApS
APSDissolvedCVR 25198956Tuborg Sundpark 10, 1. thManufacture of perfumes and toilet preparations · NACE 2042Est. 20001 employees
Revenue 2022
DKK -8K
-28% vs 2021
EBITDA margin
100.0%
+28% vs 2021
Equity ratio
91.5%
Financial strength
Net profit 2022
DKK -7K
+29% vs 2021
| Revenue | DKK -8K | -28% |
| EBITDA | DKK -8K | +28% |
| Net profit | DKK -7K | +29% |
| Total assets | DKK 899K | +0% |
| Equity | DKK 823K | -1% |
| Employees | 1 | — |
Legal name
LANGEPHARM ApS
CVR number
25198956
Legal form
Anpartsselskab
NACE code
2042 · Manufacture of perfumes and toilet preparations
Founded
14. februar 2000
Share capital
DKK 150.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Address
Tuborg Sundpark 10, 1. th
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 60 | 47 | 102 | 129 | 197 | 205 | 184 | -33 | -12 | -8 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -90 | -120 | -0 | -0 | -0 | -0 |
| EBITDA | 6 | 60 | 47 | 102 | 166 | 107 | 85 | 184 | -33 | -12 | -8 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 6 | 60 | 47 | 102 | 166 | 107 | 85 | 184 | -33 | -12 | -8 |
| Net financials | 1 | -0 | -0 | -1 | -19 | 27 | 29 | 23 | 0 | -0 | -0 |
| Profit before tax | 7 | 60 | 47 | 101 | 147 | 134 | 115 | 207 | -33 | -12 | -8 |
| Tax | 2 | 14 | 9 | 24 | 32 | 29 | 25 | 46 | -7 | -3 | -2 |
| Net profit | 5 | 46 | 37 | 77 | 115 | 104 | 89 | 162 | -26 | -9 | -7 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 566 | 632 | 651 | 749 | 875 | 988 | 1.075 | 1.257 | 938 | 896 | 899 |
| Equity | 473 | 518 | 556 | 633 | 748 | 852 | 941 | 1.103 | 839 | 830 | 823 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 93 | 113 | 95 | 116 | 127 | 136 | 134 | 154 | 99 | 66 | 76 |
| Total debt | 93 | 113 | 95 | 116 | 127 | 136 | 134 | 154 | 99 | 66 | 76 |
EBITDA margin
-846800.0%
This company
15.8%
Market median
-5359594% vs market
20122022
Equity ratio
91.5%
This company
38.2%
Market median
+140% vs market
20122022
Return on equity
-0.8%
This company
18.4%
Market median
-104% vs market
20122022
Net profit margin
-661000.0%
This company
8.1%
Market median
-8160594% vs market
20122022
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20122022
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
20122022
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RJ Founder | Founder | 2000 | — | — |
KB Audit | Audit | 2003 | — | — |
HO Management | Management | 2003 | — | — |
FH Audit | Audit | 2000 | — | — |
GR Chief Executive Officer | Chief Executive Officer | 2004 | — | — |
NS Chief Executive Officer | Chief Executive Officer | 2000 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2003 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
LANGE HOLDING ApS | Company | 100.0% | 100.0% | 2000 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LANGEPHARM ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Richard Jørgen Lange Wantzin | Founder | 0 companies |
| Karl-Alfred Brylle | Audit | 0 companies |
| Hans Ole Svendsen | Management | 0 companies |
| Flemming Hess | Audit | 0 companies |
| Gunhild Regitze Skovgaard | Chief Executive Officer | 0 companies |
| Nicholas Sigurd Lange Wantzin | Chief Executive Officer | 0 companies |
| Steffen Møller | Board of Directors | 0 companies |